Risk Phenotypes, Comorbidities, Pharmacotherapy, and Electroconvulsive Therapy (ECT) in a Cohort with Difficult-to-Treat Depression in Comparison to an Unmedicated Control Group

Weber,Heike

DOI: https://doi.org/10.1055/a-2292-1438

2024-05-03

Pharmacopsychiatry

Abstract:Background Approximately 15–25% of depressed patients suffer from difficult-to-treat depression (DTD). Patients with DTD require a thorough examination to avoid the oversight of treatable (psychiatric/somatic) comorbidities or (pseudo-)resistance to antidepressant drugs (ADs). Polymorphisms of the cytochrome P450 (CYP) enzymes 2D6 and 2C19, which play a major role in the metabolism of ADs, may contribute to resistance to ADs. Patients with DTD might benefit from electroconvulsive therapy (ECT). Methods We enrolled 109 patients with DTD and 29 untreated depressed controls (UDC). We assessed risk phenotypes, comorbidities, and treatment, including ECT. We also performed pharmacokinetic analyses of CYP2D6 and CYP2C19. Results DTD patients significantly more often suffered from comorbid psychiatric diseases, especially ICD-10: F40-F48 (DTD:40.4%, UDC:17.2%, OR 11.87, p =0.011) than UDC patients. DTD patients receiving ECT were more likely to achieve remission (37.7% vs. 11.8%, OR=3.96, p =0.023). Treatment with ADs did not differ between remitters and non-remitters. No significant differences were observed in the distribution of CYP2D6 and CYP2C19 variants between both groups. Conclusion Patients with DTD appear to experience comorbid neurotic stress and somatoform disorders (ICD-10: F40 – F48) more frequently. Therefore, a comprehensive differential diagnosis is crucial when patients do not respond sufficiently to antidepressant medication. Genotyping CYP2D6 and CYP2C19 should be considered. Received: 09 August 2023 Received: 07 March 2024 Accepted: 11 March 2024 Article published online: 02 May 2024 © 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/). Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

pharmacology & pharmacy,psychiatry

What problem does this paper attempt to address?

### Problems the paper attempts to solve

This paper mainly explores the clinical features, comorbidities, drug treatment, and the effect of electroconvulsive therapy (ECT) in patients with difficult - to - treat depression (DTD). Specifically, the researchers attempt to answer the following key questions:

1. **Risk phenotypes and comorbidities**:
- Are there significant differences in risk phenotypes and comorbidities between patients with difficult - to - treat depression and an untreated depression control group?
- Pay special attention to the distribution of neurotic stress and somatoform disorders (ICD - 10: F40 - F48) between the two groups.

2. **Treatment effects**:
- Are patients with difficult - to - treat depression who receive electroconvulsive therapy more likely to achieve remission than those who do not receive electroconvulsive therapy?
- Do different types of antidepressant drugs have an impact on the remission rate of patients with difficult - to - treat depression?

3. **Pharmacokinetic gene variants**:
- Are there significant differences in CYP2D6 and CYP2C19 gene metabolic phenotypes between patients with difficult - to - treat depression and an untreated depression control group?
- Does drug - gene interaction affect the remission rate of patients with difficult - to - treat depression?

### Research background

- **Difficult - to - treat depression (DTD)**: Approximately 15 - 25% of patients with depression have difficult - to - treat depression. These patients do not respond well to conventional treatment and require more comprehensive evaluation to avoid missing the diagnosis of treatable comorbidities or pseudo - resistance.
- **CYP enzyme polymorphisms**: CYP2D6 and CYP2C19 enzymes play an important role in the metabolism of antidepressant drugs, and their polymorphisms may lead to drug resistance.
- **Electroconvulsive therapy (ECT)**: ECT is considered one of the most effective and well - established methods for treating difficult - to - treat depression at present.

### Methods

- **Research design**: This is a cross - sectional study that included 109 patients with difficult - to - treat depression and 29 untreated depression control group patients.
- **Diagnosis and assessment**: Use ICD - 10 and SCID for diagnosis, and assess the severity of depressive symptoms through MADRS and BDI - II.
- **Genetic testing**: Genotype CYP2D6 and CYP2C19 genes and analyze their impact on drug metabolism.
- **Statistical analysis**: Use a logistic regression model to analyze the impact of phenotypes, comorbidities, and metabolic phenotypes on the development of difficult - to - treat depression, as well as the impact of treatment interventions (ECT and drug treatment) on the remission rate.

### Results

- **Risk phenotypes and comorbidities**:
- Patients with difficult - to - treat depression are more likely to have neurotic stress and somatoform disorders (ICD - 10: F40 - F48), and the proportion is significantly higher than that in the control group (OR = 4.21, p = 0.011).
- Patients with difficult - to - treat depression are more likely to have other somatic diseases, such as endocrine diseases and cardiovascular diseases (OR = 6.95, p = 5.2×10^−5).

- **Treatment effects**:
- The proportion of patients with difficult - to - treat depression who receive electroconvulsive therapy and achieve remission is significantly higher than that of patients who do not receive electroconvulsive therapy (37.7% vs. 11.8%, OR = 3.96, p = 0.023).
- Patients using benzodiazepines/Z - drugs (OR = 4.01, p = 0.006) have a higher remission rate in drug treatment, but this result is not significant after adjustment (p_adjusted = 0.080).

- **Pharmacokinetic gene variants**:
- There are no significant differences in the distribution of CYP2D6 and CYP2C19 gene metabolic phenotypes between patients with difficult - to - treat depression and the control group.
- After correction for drug - gene interaction, poor CYP2D6 metabolizers are more common in patients with difficult - to - treat depression (OR = 16.23, p = 0.016), but this result is not significant after adjustment (p_adjusted = 0.082).

### Conclusions

- **Patients with difficult - to - treat depression**: They are more likely to have neurotic stress and somatoform disorders, so comprehensive differential diagnosis during the treatment process is very important.
- **Electroconvulsive therapy**